Evidence map›Paper›PMID 40511682›Full record

ArticleeLife2025

Artificial intelligence approaches for tumor phenotype stratification from single-cell transcriptomic data.

Namrata Bhattacharya, Anja Rockstroh, Sanket Suhas Deshpande, Sam Koshy Thomas, Anunay Yadav, Chitrita Goswami, Smriti Chawla, Pierre Solomon, Cynthia Fourgeux, Gaurav Ahuja and 7 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Namrata BhattacharyaAustralian Prostate Cancer Research Centre-Queensland, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Australia.ORCID https://orcid.org/0000-0002-5666-2551
Anja RockstrohAustralian Prostate Cancer Research Centre-Queensland, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Australia.
Sanket Suhas DeshpandeDepartment of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, India.
Sam Koshy ThomasSchool of Mathematical Sciences, The University of Adelaide, Adelaide, Australia.
Anunay YadavDepartment of Computer Science and Engineering, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, India.
Chitrita GoswamiDepartment of Computer Science and Engineering, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, India.
Smriti ChawlaCenter for Computational Biomedicine, Harvard Medical School, Boston, United States.
Pierre SolomonNantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR, Nantes, France.
Cynthia FourgeuxNantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR, Nantes, France.
Gaurav AhujaDepartment of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, India.ORCID https://orcid.org/0000-0002-2837-9361
Brett HollierAustralian Prostate Cancer Research Centre-Queensland, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Australia.
Himanshu KumarLaboratory of Immunology and Infectious Disease Biology, Department of Biological Sciences, Indian Institute of Science Education and Research (IISER), Bhopal, India.ORCID https://orcid.org/0000-0001-5246-2694
Antoine RoquillyNantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR, Nantes, France.ORCID https://orcid.org/0000-0002-1029-6242
Jeremie PoschmannNantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR, Nantes, France.ORCID https://orcid.org/0000-0002-9613-5297
Melanie LehmanAustralian Prostate Cancer Research Centre-Queensland, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Australia.
Colleen C NelsonAustralian Prostate Cancer Research Centre-Queensland, Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Australia.
Debarka SenguptaDepartment of Computer Science and Engineering, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), Okhla, Phase III, New Delhi, India.ORCID https://orcid.org/0000-0002-6353-5411

Funding

Department of Biotechnology IC-12044(12)/4/2022-ICD-DBTScience and Engineering Research Board CRG/2022/007706
6 · The paper itself

Abstract

Single-cell RNA-sequencing (scRNA-seq) coupled with robust computational analysis facilitates the characterization of phenotypic heterogeneity within tumors. Current scRNA-seq analysis pipelines are capable of identifying a myriad of malignant and non-malignant cell subtypes from single-cell profiling of tumors. However, given the extent of intra-tumoral heterogeneity, it is challenging to assess the risk associated with individual cell subpopulations, primarily due to the complexity of the cancer phenotype space and the lack of clinical annotations associated with tumor scRNA-seq studies. To this end, we introduce SCellBOW, a scRNA-seq analysis framework inspired by document embedding techniques from the domain of Natural Language Processing (NLP). SCellBOW is a novel computational approach that facilitates effective identification and high-quality visualization of single-cell subpopulations. We compared SCellBOW with existing best practice methods for its ability to precisely represent phenotypically divergent cell types across multiple scRNA-seq datasets, including our in-house generated human splenocyte and matched peripheral blood mononuclear cell (PBMC) dataset. For tumor cells, SCellBOW estimates the relative risk associated with each cluster and stratifies them based on their aggressiveness. This is achieved by simulating how the presence or absence of a specific cell subpopulation influences disease prognosis. Using SCellBOW, we identified a hitherto unknown and pervasive AR-/NE

Indexed as

Artificial IntelligenceNeoplasmsSingle-Cell AnalysisTranscriptomeComputational BiologyGene Expression ProfilingHumansMalePhenotypeSequence Analysis, RNAcomputational biologyhumanlanguage modelmarker-freeprostate cancerrisk stratificationsingle-cell RNA-seqsystems biologytransfer learning

Identifiers

PMID40511682
PMCPMC12165692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.